Tech Company Financing Transactions
Vitruvias Therapeutics Funding Round
Vitruvias Therapeutics, based in Auburn, raised $11.5 million from JW Asset Management, Perceptive Advisors and private investors.
Transaction Overview
Company Name
Announced On
1/6/2018
Transaction Type
Venture Equity
Amount
$11,500,000
Round
Series A
Investors
JW Asset Management (Lead Investor) (Jason Wild)
Perceptive Advisors (Lead Investor) (Michael Altman)
Proceeds Purpose
Vitruvias Therapeutics will primarily use this investment to complete multiple projects already under development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2138 Moores Mill Rd. B
Auburn, AL 36830
USA
Auburn, AL 36830
USA
Phone
Website
Email Address
Overview
Vitruvias is a specialty generic pharmaceutical business focused on the development and marketing of generic products with either (i) complex APIs that are difficult to source, or (ii) finished dosage forms that are inherently difficult to manufacture.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Carl Whatley
Co-Founder
Bryce Harvey
President
Roger Graben
VP - Bus. Development
Kevin Swiss
VP - Regulatory Affairs
Lisa Apolis
Browse more venture capital transactions:
Prev: 1/6/2018: Frank venture capital transaction
Next: 1/6/2018: VICIS venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs